Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α
- 1 July 2010
- journal article
- research article
- Published by Taylor & Francis in mAbs
- Vol. 2 (4), 428-439
- https://doi.org/10.4161/mabs.12304
Abstract
We prepared and characterized golimumab (CNTO148), a human IgG1 tumor necrosis factor alpha (TNFα) antagonist monoclonal antibody chosen for clinical development based on its molecular properties. Golimumab was compared with infliximab, adalimumab and etanercept for affinity and in vitro TNFα neutralization. The affinity of golimumab for soluble human TNFα, as determined by surface plasmon resonance, was similar to that of etanercept (18 pM versus 11 pM), greater than that of infliximab (44 pM) and significantly greater than that of adalimumab (127 pM, p=0.018). The concentration of golimumab necessary to neutralize TNFα-induced E-selectin expression on human endothelial cells by 50% was significantly less than those for infliximab (3.2 fold; p=0.017) and adalimumab (3.3-fold; p=0.008) and comparable to that for etanercept. The conformational stability of golimumab was greater than that of infliximab (primary melting temperature [Tm] 74.8 °C vs. 69.5 °C) as assessed by differential scanning calorimetry. ...Keywords
This publication has 39 references indexed in Scilit:
- Inhibition of TNF-α reduces transplant arteriosclerosis in a murine aortic transplant modelTransplant International, 2009
- Differences in binding and effector functions between classes of TNF antagonistsCytokine, 2009
- Evaluation of the anti‐inflammatory effect of infliximab in a mouse model of acute asthmaRespirology, 2008
- Tumor necrosis factor as a therapeutic target of rheumatologic diseaseEmerging Therapeutic Targets, 2007
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2007
- TNFα blockade in human diseases: Mechanisms and future directionsClinical Immunology, 2007
- FcRn: the neonatal Fc receptor comes of ageNature Reviews Immunology, 2007
- Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2004
- Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgMInternational Immunology, 1994
- A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contactCell, 1990